Trial Profile
Extended Dose Frequency 1st-Line Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (Myocet)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MyoPac
- 07 Jul 2010 Planned end date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 03 Jul 2008 New trial record.